SKN | Citigroup Raises Abbott Laboratories Price Target to $112, Maintains Buy Rating

Key Takeaways:

• Citigroup raised its price target on Abbott Laboratories to $112 from $108, while maintaining a Buy rating.
• The revised target reflects confidence in Abbott’s diversified healthcare portfolio, including medical devices, diagnostics, nutrition, and established pharmaceuticals.
• Investors continue to monitor demand for cardiovascular devices, diabetes care technologies, product innovation, and international expansion as key drivers of future growth.

Citigroup Reaffirms Positive Outlook on Abbott Laboratories

Citigroup has increased its price target on Abbott Laboratories to $112 from $108 while reaffirming its Buy rating, reflecting continued confidence in the company’s long-term growth strategy and diversified healthcare business. The revised valuation underscores expectations that Abbott will continue delivering resilient financial performance through innovation, global expansion, and balanced revenue generation across its operating segments.

The maintained Buy rating highlights Citigroup’s view that Abbott remains well-positioned to benefit from growing healthcare demand despite macroeconomic uncertainties and evolving industry dynamics.

Diversified Healthcare Platform Provides Resilience

Abbott Laboratories operates one of the industry’s most diversified healthcare portfolios, with businesses spanning medical devices, diagnostics, nutritional products, and established pharmaceuticals. This broad operating model helps reduce dependence on any single product category while generating stable cash flows across multiple healthcare markets.

Its global footprint and extensive product portfolio continue to support consistent earnings as healthcare systems increasingly prioritize preventative care, chronic disease management, and advanced diagnostic technologies.

Medical Devices Continue to Lead Growth

Abbott’s medical device business remains a key growth engine, supported by strong demand across cardiovascular care, structural heart therapies, electrophysiology, and diabetes management.

The company’s FreeStyle Libre continuous glucose monitoring platform continues to be one of its flagship products, benefiting from increasing adoption among patients and healthcare providers worldwide. Ongoing innovation in minimally invasive cardiovascular technologies and rhythm management solutions also strengthens Abbott’s competitive position within the medical technology sector.

Innovation and Global Expansion Support Long-Term Strategy

Abbott continues investing in research and development to expand its portfolio of innovative healthcare solutions. New product launches, regulatory approvals, and international market expansion remain central to the company’s long-term growth strategy.

The company is also advancing its digital health capabilities by integrating connected technologies that improve patient monitoring, disease management, and clinical decision-making. These initiatives are expected to enhance both patient outcomes and operational efficiency across healthcare systems.

Investors Monitor Product Performance and Earnings

Looking ahead, investors will closely monitor quarterly earnings, medical device sales, diagnostic testing demand, nutritional product performance, and progress across Abbott’s product development pipeline.

Market participants are also expected to follow reimbursement policies, regulatory developments, healthcare spending trends, and the pace of innovation within the medical technology industry as important indicators of future financial performance.

Abbott’s continued execution across its diversified business segments will remain central to sustaining long-term earnings growth.

Closing Insights

Citigroup’s decision to raise its price target while maintaining a Buy rating reflects continued confidence in Abbott Laboratories’ diversified healthcare platform, innovation pipeline, and global growth strategy. Supported by leadership in medical devices, diagnostics, nutrition, and digital health technologies, Abbott remains well-positioned to capitalize on expanding healthcare demand while delivering sustainable long-term value for shareholders.

For a confidential discussion regarding healthcare sector strategy, medical technology innovation, diagnostics markets, life sciences investments, or global healthcare growth opportunities, contact our senior advisory team.